These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 25111582)

  • 1. Nonmyeloablative allogeneic hematopoietic stem cell transplantation for GATA2 deficiency.
    Grossman J; Cuellar-Rodriguez J; Gea-Banacloche J; Zerbe C; Calvo K; Hughes T; Hakim F; Cole K; Parta M; Freeman A; Holland SM; Hickstein DD
    Biol Blood Marrow Transplant; 2014 Dec; 20(12):1940-8. PubMed ID: 25111582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allogeneic Hematopoietic Stem Cell Transplantation for GATA2 Deficiency Using a Busulfan-Based Regimen.
    Parta M; Shah NN; Baird K; Rafei H; Calvo KR; Hughes T; Cole K; Kenyon M; Schuver BB; Cuellar-Rodriguez J; Zerbe CS; Holland SM; Hickstein DD
    Biol Blood Marrow Transplant; 2018 Jun; 24(6):1250-1259. PubMed ID: 29412158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful allogeneic hematopoietic stem cell transplantation for GATA2 deficiency.
    Cuellar-Rodriguez J; Gea-Banacloche J; Freeman AF; Hsu AP; Zerbe CS; Calvo KR; Wilder J; Kurlander R; Olivier KN; Holland SM; Hickstein DD
    Blood; 2011 Sep; 118(13):3715-20. PubMed ID: 21816832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-dose total body irradiation, fludarabine, and antithymocyte globulin conditioning for nonmyeloablative allogeneic transplantation.
    Grosskreutz C; Ross V; Scigliano E; Fruchtman S; Isola L
    Biol Blood Marrow Transplant; 2003 Jul; 9(7):453-9. PubMed ID: 12869959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Related and unrelated nonmyeloablative hematopoietic stem cell transplantation for malignant diseases.
    Georges GE; Maris M; Sandmaier BM; Malone DG; Feinstein L; Niederweiser D; Shizuru JA; McSweeney PA; Chauncey TR; Agura E; Little MT; Sahebi F; Hegenbart U; Pulsipher MA; Bruno B; Forman S; Woolfrey AE; Radich JP; Blume KG; Storb R
    Int J Hematol; 2002 Aug; 76 Suppl 1():184-9. PubMed ID: 12430851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful Myeloablative Matched Unrelated Donor Hematopoietic Stem Cell Transplantation in a Young Girl With GATA2 Deficiency and Emberger Syndrome.
    Ramzan M; Lowry J; Courtney S; Krueger J; Schechter Finkelstein T; Ali M
    J Pediatr Hematol Oncol; 2017 Apr; 39(3):230-232. PubMed ID: 28234738
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced-intensity allogeneic transplant in patients older than 55 years: unrelated umbilical cord blood is safe and effective for patients without a matched related donor.
    Majhail NS; Brunstein CG; Tomblyn M; Thomas AJ; Miller JS; Arora M; Kaufman DS; Burns LJ; Slungaard A; McGlave PB; Wagner JE; Weisdorf DJ
    Biol Blood Marrow Transplant; 2008 Mar; 14(3):282-9. PubMed ID: 18275894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sirolimus, tacrolimus, and low-dose methotrexate as graft-versus-host disease prophylaxis in related and unrelated donor reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation.
    Alyea EP; Li S; Kim HT; Cutler C; Ho V; Soiffer RJ; Antin JH
    Biol Blood Marrow Transplant; 2008 Aug; 14(8):920-6. PubMed ID: 18640576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy.
    Koh LP; Chen CS; Tai BC; Hwang WY; Tan LK; Ng HY; Linn YC; Koh MB; Goh YT; Tan B; Lim S; Lee YM; Tan KW; Liu TC; Ng HJ; Loh YS; Mow BM; Tan DC; Tan PH
    Biol Blood Marrow Transplant; 2007 Jul; 13(7):790-805. PubMed ID: 17580257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Total Body Irradiation-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Matched Sibling Donors.
    Solomon SR; Sizemore CA; Sanacore M; Zhang X; Brown S; Holland HK; Morris LE; Bashey A
    Biol Blood Marrow Transplant; 2015 Jul; 21(7):1299-307. PubMed ID: 25797174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tacrolimus and mycophenolate mofetil after nonmyeloablative matched-sibling donor allogeneic stem-cell transplantations conditioned with fludarabine and low-dose total body irradiation.
    Nieto Y; Patton N; Hawkins T; Spearing R; Bearman SI; Jones RB; Shpall EJ; Rabinovitch R; Zeng C; Barón A; McSweeney PA
    Biol Blood Marrow Transplant; 2006 Feb; 12(2):217-25. PubMed ID: 16443519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning.
    Barker JN; Weisdorf DJ; DeFor TE; Blazar BR; Miller JS; Wagner JE
    Blood; 2003 Sep; 102(5):1915-9. PubMed ID: 12738676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Donor source and post-transplantation cyclophosphamide influence outcome in allogeneic stem cell transplantation for GATA2 deficiency.
    Nichols-Vinueza DX; Parta M; Shah NN; Cuellar-Rodriguez JM; Bauer TR; West RR; Hsu AP; Calvo KR; Steinberg SM; Notarangelo LD; Holland SM; Hickstein DD
    Br J Haematol; 2022 Jan; 196(1):169-178. PubMed ID: 34580862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A well-tolerated regimen of 800 cGy TBI-fludarabine-busulfan-ATG for reliable engraftment after unmanipulated haploidentical peripheral blood stem cell transplantation in adult patients with acute myeloid leukemia.
    Yahng SA; Kim JH; Jeon YW; Yoon JH; Shin SH; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Park CW; Kim HJ
    Biol Blood Marrow Transplant; 2015 Jan; 21(1):119-29. PubMed ID: 25300871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treosulfan and Fludarabine Conditioning for Hematopoietic Stem Cell Transplantation in Children with Primary Immunodeficiency: UK Experience.
    Slatter MA; Rao K; Abd Hamid IJ; Nademi Z; Chiesa R; Elfeky R; Pearce MS; Amrolia P; Worth A; Flood T; Abinun M; Hambleton S; Qasim W; Gaspar HB; Cant AJ; Gennery AR; Veys P
    Biol Blood Marrow Transplant; 2018 Mar; 24(3):529-536. PubMed ID: 29155317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of matched unrelated donors compared with matched related donors is associated with lower relapse and superior progression-free survival after reduced-intensity conditioning hematopoietic stem cell transplantation.
    Ho VT; Kim HT; Aldridge J; Liney D; Kao G; Armand P; Koreth J; Cutler C; Ritz J; Antin JH; Soiffer RJ; Alyea EP
    Biol Blood Marrow Transplant; 2011 Aug; 17(8):1196-204. PubMed ID: 21193054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Matched related and unrelated donor hematopoietic stem cell transplantation for DOCK8 deficiency.
    Cuellar-Rodriguez J; Freeman AF; Grossman J; Su H; Parta M; Murdock H; Shah N; Bollard C; Kong HH; Moutsopoulos N; Stone K; Gea-Banacloche J; Holland SM; Hickstein DD
    Biol Blood Marrow Transplant; 2015 Jun; 21(6):1037-45. PubMed ID: 25636378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful Nonmyeloablative Allogeneic Stem Cell Transplant in a Child With Emberger Syndrome and GATA2 Mutation.
    Rastogi N; Abraham RS; Chadha R; Thakkar D; Kohli S; Nivargi S; Prakash Yadav S
    J Pediatr Hematol Oncol; 2018 Aug; 40(6):e383-e388. PubMed ID: 29189513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Haploidentical Related Donor Hematopoietic Stem Cell Transplantation for Dedicator-of-Cytokinesis 8 Deficiency Using Post-Transplantation Cyclophosphamide.
    Shah NN; Freeman AF; Su H; Cole K; Parta M; Moutsopoulos NM; Baris S; Karakoc-Aydiner E; Hughes TE; Kong HH; Holland SM; Hickstein DD
    Biol Blood Marrow Transplant; 2017 Jun; 23(6):980-990. PubMed ID: 28288951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders.
    Laport GG; Sandmaier BM; Storer BE; Scott BL; Stuart MJ; Lange T; Maris MB; Agura ED; Chauncey TR; Wong RM; Forman SJ; Petersen FB; Wade JC; Epner E; Bruno B; Bethge WA; Curtin PT; Maloney DG; Blume KG; Storb RF
    Biol Blood Marrow Transplant; 2008 Feb; 14(2):246-55. PubMed ID: 18215785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.